Raquel González|Ghyslain Mombo?Ngoma|Smaïla Ouédraogo|Mwaka A. Kakolwa|Salim Abdulla|Manfred Accrombessi|John J. Aponte|Daisy Akerey-Diop|Arti Basra|Valérie Briand|Mesküre Capan|Michel Cot|Abdunoor M. Kabanywanyi|Christian Kleine|Peter G. Kremsner|Eusébio Macete|Jean-Rodolphe Mackanga|Achille Massougbodgi|Alfredo Mayor|Arsénio Nhacolo|Golbahar Pahlavan|Michael Ramharter|Maria Rosario|Esperança Sevene|Anifa Valá|Rella Zoleko?Manego|Clara Menéndez
Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial
Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre|Albert Schweitzer Hospital|Centre de Recherche Médicales de Lambaréné|University of Tübingen|Université d'Abomey-Calavi|Institut de Recherche pour le Développement|Ifakara Health Institute|Ifakara Health Institute|Université d'Abomey-Calavi|Institut de Recherche pour le Développement|Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre|Albert Schweitzer Hospital|Centre de Recherche Médicales de Lambaréné|University of Tübingen|Albert Schweitzer Hospital|Centre de Recherche Médicales de Lambaréné|University of Tübingen|Délégation Paris 5|Université Paris Cité|Institut de Recherche pour le Développement|Albert Schweitzer Hospital|Centre de Recherche Médicales de Lambaréné|University of Tübingen|Université Paris Cité|Institut de Recherche pour le Développement|Délégation Paris 5|Ifakara Health Institute|Albert Schweitzer Hospital|Centre de Recherche Médicales de Lambaréné|University of Tübingen|Albert Schweitzer Hospital|Centre de Recherche Médicales de Lambaréné|University of Tübingen|Manhiça Health Research Centre|Albert Schweitzer Hospital|Centre de Recherche Médicales de Lambaréné|University of Tübingen|Université d'Abomey-Calavi|Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre|Manhiça Health Research Centre|Barcelona Institute for Global Health|Universitat de Barcelona|Albert Schweitzer Hospital|Centre de Recherche Médicales de Lambaréné|University of Tübingen|Medical University of Vienna|Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre|Manhiça Health Research Centre|Manhiça Health Research Centre|University of Tübingen|Centre International de Recherches Médicales de Franceville|Barcelona Institute for Global Health|Universitat de Barcelona|Manhiça Health Research Centre
intermittent preventive treatment pregnancy iptp sulfadoxinepyrimethamine sp recommended prevent malaria african pregnant women spread sp parasite resistance raised concerns regarding longterm use ipt mefloquine mq promising available alternatives sp based safety profile long halflife high efficacy africa evaluated safety efficacy mq iptp compared sp hivnegative womena total 4749 pregnant women enrolled openlabel randomized clinical trial conducted benin gabon mozambique tanzania comparing twodose mq sp iptp mq tolerability two different regimens study arms 1 sp 2 single dose mq 15 mgkg 3 splitdose mq context long lasting insecticide treated nets difference low birth weight prevalence primary study outcome groups 3602778 130 mq group 1771398 127 sp group risk ratio rr 102 95 ci 086122 p080 itt analysis women receiving mq reduced risks parasitemia 631372 46 sp group 882737 32 mq group rr 070 95 ci 051096 p003 anemia delivery 6091380 441 sp group 11102743 405 mq group rr 092 95 ci 085099 p003 reduced incidence clinical malaria 965518 malaria episodes personyear pyar sp group 13011032 episodes pyar mq group rr 067 95 ci 052088 p0004 allcause outpatient attendances pregnancy 8505578 outpatients visits pyar sp group 148011101 visits pyar mq group rr 086 078095 p0003 differences prevalence placental infection adverse pregnancy outcomes groups tolerability poorer two mq groups compared sp frequently reported related adverse events dizziness ranging 339 355 dose 1 160 208 dose 2 vomiting 302 317 dose 1 153 174 dose 2 similar proportions full split mq arms openlabel design limitation study affects mainly safety assessmentwomen taking mq iptp 15 mgkg context long lasting insecticide treated nets similar prevalence rates low birth weight taking sp iptp mq recipients less clinical malaria sp recipients pregnancy outcomes safety profile similar mq poorer tolerability even splitting dose two days results support change current iptp policyclinicaltrialsgov nct 00811421 pan african clinical trials registry pactr 2010020001429343 please see later article editors summary